Enovis Corporation Raises 2026 EPS Guidance and Announces $200 Million Share Repurchase Program
Enovis Corporation (ENOV) has updated its financial outlook, raising its 2026 earnings per share (EPS) guidance to a range of $3.58 to $3.79. This optimistic revision comes alongside the company's authorization of a new $200 million share repurchase program, signaling management's confidence in long-term value creation and cash flow. During its third quarter performance review, CEO Damien McDonald reported organic growth of 5%. This growth was driven primarily by the Recon segment, which saw a 6% increase, while the P&R segment grew by 3%. The company continues to focus on expanding its market presence through key product lines like Nebula in the Hips and Knees category.
Tickers: $ENOV
Topics: medical devices organic growth quarterly earnings
Read the full article at Seeking Alpha
Part of the story TKO Group Holdings Raises 2026 Revenue Guidance and Announces Aggressive Share Buyback Program (3 articles)